CT 1812

Drug Profile

CT 1812

Alternative Names: CT-1812; Elayta

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cognition Therapeutics
  • Class Antidementias; Small molecules
  • Mechanism of Action Sigma-2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Cognition disorders

Most Recent Events

  • 05 Jun 2018 Pharmacodynamics data from a preclinical study in Alzheimer's disease released by Cognition Therapeutics
  • 16 May 2018 Cognition Therapeutics initiates a phase I trial for Alzheimer's disease (In adults, In the elderly) in USA (NCT03522129)
  • 11 May 2018 Cognition Therapeutics plans a phase I trial for Alzheimer's disease in USA , (NCT03522129)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top